Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT-XPB: Spironolactone Impact on XPB-1 Subunit in HIV
NCT07415811Enrolling by invitation
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of spironolactone in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: XPB Protein Degradation in CD4+ T Cells at 4 weeks. Started Jul 2024; status: enrolling by invitation.
02
Drugs
spironolactone
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07415811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415811.